ROIV - Roivant Sciences GAAP EPS of $6.03 beats by $5.54 revenue of $37.14M beats by $7.32M
2024-02-13 07:06:27 ET
More on Roivant Sciences
- Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas
- Roivant Sciences: Why Its 'Vant' Biotech Model Is A Buy
- Roivant Sciences Q3 2024 Earnings Preview
- Arbutus Biopharma gains after Markman hearing on Thursday in Moderna dispute
- Seeking Alpha’s Quant Rating on Roivant Sciences